153 related articles for article (PubMed ID: 29194861)
21. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study.
Mgaieth S; Kemp W; Gow P; Fink M; Lubel J; Nicoll A; Gazzola A; Hong T; Ryan M; Knight V; Dev AT; Sood S; Bell S; Paul E; Roberts SK
J Viral Hepat; 2017 Nov; 24(11):982-989. PubMed ID: 28414893
[TBL] [Abstract][Full Text] [Related]
22. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Waziry R; Gomaa A; Waked I; Dore GJ
Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913
[TBL] [Abstract][Full Text] [Related]
23. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
24. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006.
Walter SR; Thein HH; Amin J; Gidding HF; Ward K; Law MG; George J; Dore GJ
J Hepatol; 2011 May; 54(5):879-86. PubMed ID: 21145812
[TBL] [Abstract][Full Text] [Related]
25. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
26. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
27. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
28. Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study.
Yang JD; Ahmed Mohammed H; Harmsen WS; Enders F; Gores GJ; Roberts LR
J Clin Gastroenterol; 2017 Sep; 51(8):742-748. PubMed ID: 28445235
[TBL] [Abstract][Full Text] [Related]
29. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
30. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
31. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
[TBL] [Abstract][Full Text] [Related]
32. Short-Term Incidence of Sequelae of HCV Infection Among Medicaid Beneficiaries in Oregon.
Jindai K; Crawford C; Thomas AR
Public Health Rep; 2019; 134(1):81-88. PubMed ID: 30508493
[TBL] [Abstract][Full Text] [Related]
33. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study.
Hallager S; Ladelund S; Kjaer M; Madsen LG; Belard E; Laursen AL; Gerstoft J; Røge BT; Grønbaek KE; Krarup HB; Christensen PB; Weis N
J Viral Hepat; 2018 Jan; 25(1):47-55. PubMed ID: 28750141
[TBL] [Abstract][Full Text] [Related]
36. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
37. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis.
El Kassas M; Funk AL; Salaheldin M; Shimakawa Y; Eltabbakh M; Jean K; El Tahan A; Sweedy AT; Afify S; Youssef NF; Esmat G; Fontanet A
J Viral Hepat; 2018 Jun; 25(6):623-630. PubMed ID: 29274197
[TBL] [Abstract][Full Text] [Related]
38. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan.
Suruki R; Hayashi K; Kusumoto K; Uto H; Ido A; Tsubouchi H; Stuver SO
Int J Cancer; 2006 Jul; 119(1):192-5. PubMed ID: 16432841
[TBL] [Abstract][Full Text] [Related]
39. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C and hepatitis B-related mortality in Spain.
García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
